Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Intel Strategy for Achieving Wealth and Off Topic -- Ignore unavailable to you. Want to Upgrade?

To: Sonny McWilliams who wrote (18681)	3/25/1998 10:46:00 AM
From: Sonki	Read Replies (2) \| Respond to of 27012

LLY is now where i sold off last summer and want to get back into it. Pls. read BELOW when u have more time, it looks really bad for lly but it's one stock of the drugs i don't have. If wla falls more i will buy more. go intel ...$110. (i have to do M.'s job) oh. btw: i only buy SUNW to hedge my msft portfolio. it's better then buying MSFT puts. (kidding, I don't need to protect my msft). BELOW RESEARCH ALERT - Eli Lilly downgraded NEW YORK, March 25 (Reuters) - Salomon Smith Barney said on Wednesday it lowered its rating on shares of Eli Lilly and Co to outperform from buy. -- Analyst Christina Heuer said in a research note the launch of Lilly's raloxifene, or Evista, its drug to prevent osteoporosis, has been disappointing. -- She lowered 1998 Evista sales estimate to $180 million from $375 million and 2002 Evista sales estimate to the $2 billion level from the $3 billion level. -- ''Unfortunately Lilly's new drug launches are sparse until 2001, when a burst of six is anticipated,'' she said. ''So there are no other major new drug introductions to make up for the shortfall in Evista.'' -- Heuer said she had thought a large pool of post-menopausal women who had discontinued estrogen replacement therapy due to breast cancer risk would flock to Evista to prevent osteoporosis, but this has not occured. -- Shortfall in Evista increases Lilly's exposure to Prozac generic cannibalization risk, she said.